<DOC>
	<DOCNO>NCT00686959</DOCNO>
	<brief_summary>This study compare overall survival participant locally-advanced , Stage III Non-Small Cell Lung Cancer ( NSCLC ) nonsquamous cell histology .</brief_summary>
	<brief_title>Chemotherapy Radiation Treating Participants With Stage 3 Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Participants must Stage IIIA IIIIB NSCLC nonsquamous type Participants must measureable tumor lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) guideline disease evaluate computerized tomography ( CT ) scan Participants must physically mobile , take care must able perform light activity , light housework office work Participants must 18 year age old Participants must lose 10 % body weight previous 3 month Women must sterile , postmenopausal , contraception , men must sterile contraception Participants ' test result assess function blood form tissue , kidney , liver , lung must satisfactory Participants Stage IIIB NSCLC supraclavicular nodal involvement may enter study . However , participant cervical node permit . The upper border supraclavicular node must extend upper border lateral end clavicle , extend medially . Participants ongoing ( uncontrolled ) illness , include active infection , recent heart problem , psychiatric illness Participants unable take vitamin ( include injection vitamin B12 ) oral cortisone medication Participants heart attack ( myocardial infarction ) cardiac issue within 6 month trial Participants receive investigational drug within last 30 day Participants unable stop take 1.3 gram aspirin daily basis nonsteroidal antiinflammatory agent Participants disease consider surgical treatment part care plan , Pancoast superior sulcus tumor Participants prior thoracic radiation . However , prior radiotherapy allow . Participants must recover toxic effect treatment prior study enrollment . Participants may receive whole pelvis radiation radiation 25 % bone marrow . Prior radiotherapy must complete least 30 day prior study treatment . Participants radiation treatment plan would expose 35 % volume lung 20 gray ( Gy ) radiation Participants concurrent cancer another primary site require treatment kind within past 5 year . Exemptions permit casebycase basis prior approval Sponsor physician designate investigator believe participant 's risk recurrence death low . Curatively treated nonmelanoma skin cancer situ carcinoma origin allow . Participants recurrence previously resect lung cancer second primary lung cancer ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>